CNSA 001

Drug Profile

CNSA 001

Alternative Names: CNSA-001

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Censa Pharmaceuticals
  • Class Neuropsychotherapeutics
  • Mechanism of Action Mixed function oxygenase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dystonia

Most Recent Events

  • 10 Nov 2017 Phase-I clinical trials in Dystonia (In volunteers) in Australia (PO) (ACTRN12617001561370)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top